TransCode Therapeutics Advances TTX-MC138 to Phase 2a Trials After Positive Phase 1a Results in Metastatic Disease

TransCode Therapeutics Inc. has announced the completion of its Phase 1a clinical trial evaluating TTX-MC138, an investigational inhibitor of microRNA-10b, in patients with metastatic disease. The trial met its primary safety endpoint and established a recommended Phase 2 dose. Sixteen patients were treated across four escalating dose levels, with no significant treatment-related safety events or dose-limiting toxicities observed. The median treatment duration was four months, ranging from two to twelve months, and three patients remain on trial. Preliminary data showed apparent stable disease lasting over four months in 44% of patients. Ongoing data analysis and monitoring are planned, with a final clinical study report, scientific presentations, and publications to be presented in the future. The company plans to advance TTX-MC138 into a Phase 2a clinical trial to further assess efficacy across selected metastatic diseases. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE96934) on October 14, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)